Riyadh, Saudi Arabia- November 2024- Genpharm and the Saudi Society for Dermatology and Dermatological Surgery (SSDDS), have announced a strategic partnership to advance dermatological healthcare in Saudi Arabia.
The partnership will help both patients and healthcare providers alike. It will focus on implementing Continuing Medical Education (CME) activities for healthcare professionals, improving patient care, and introducing innovative treatments.
Moreover, over 150 healthcare professionals, including prominent international and local key opinion leaders in dermatology, attended the signing ceremony at the Narcissus the Royal Hotel in Riyadh. The presence of Denmark’s Ambassador to Saudi Arabia, Her Excellency Liselotte Plesner, highlighted the significance of this collaboration.
Karim Smaira, CEO and Co-founder of Genpharm, emphasized the significance of the partnership, stating, “Our partnership with SSDDS marks a significant step towards enhancing dermatological care in Saudi Arabia. We are committed to improving patient outcomes and supporting healthcare professionals with the latest advancements in treatment. Our continuous educational efforts will ensure that healthcare providers are well-equipped to offer optimized treatment to their patients.”
The event also marked Genpharm’s launch of Adtralza®, an innovative treatment for moderate to severe atopic dermatitis developed by LEO Pharma, into the Saudi market. The introduction of Adtralza® marks an innovation in atopic dermatitis therapy in Saudi Arabia, potentially improving the quality of life for those suffering from the condition.
Also Read: LEO Pharma and Emirates Dermatology Society collaborate on hand Eczema awareness in UAE
Dr. Ruaa Al Harithy, Vice President of SSDDS, highlighted the organization’s dedication to advancing dermatology, saying, “The Saudi Society of Dermatology and Dermatologic Surgery (SSDDS), a leading organization dedicated to the advancement of dermatology in the Kingdom of Saudi Arabia, is proud to highlight its ongoing commitment to the medical field and its growing partnerships with key industry players. Through education, research, and clinical excellence, the SSDDS has been at the forefront of advancing dermatological practices in the region and improving patient outcomes.’’
Dr. Abdullah Al Aqeel, President of SSDDS, expressed enthusiasm about the collaboration, noting, “We are excited about the opportunities that this partnership with Genpharm will bring. This collaboration strengthens our shared commitment to advancing skin health through innovation, education, and research.’’
Furthermore, Dr. Issam R. Hamadah, Consultant Dermatologist at King Faisal Specialist Hospital and Research Centre, remarked, “I am pleased that pharmaceutical companies are pursuing therapeutic solutions for common dermatologic diseases, which have high impact on those afflicted, their families, and society in general. Having new medications like Adtralza will be quite beneficial to all.”
